Viatris Inc.

VTRS · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Scott Franklin R · HOUSE · FL	$250K – $500K $289K – $577K today 1 filing · last May 20, 2021
Josh Gottheimer D · HOUSE · NJ	−$14K – $14K −$15K – $14K today 2 filings · last Dec 14, 2020
Gilbert Ray Cisneros, Jr. D · HOUSE · CA	−$14K – $14K −$29K – $23K today 3 filings · last Nov 18, 2025
Robert Bresnahan R · HOUSE · PA	−$14K – $14K −$35K – $21K today 2 filings · last Apr 8, 2025
Kathy E. Manning D · HOUSE · NC	−$14K – $14K −$19K – $14K today 2 filings · last Apr 30, 2021
Earl Blumenauer D · HOUSE · OR	−$14K – $14K −$26K – $18K today 2 filings · last Mar 14, 2022
Ro Khanna D · HOUSE · CA	−$98K – $98K −$154K – $165K today 14 filings · last May 27, 2026
Daniel S. Goldman D · HOUSE · NY	−$29K – $13K −$51K – $19K today 3 filings · last Apr 10, 2023

Recent transactions

Trades from Nov 17, 2020 – May 27, 2026

Politician	Type	Filed after	Amount
Ro Khanna D · HOUSE · CA-17	Sell	13 days May 27, 2026 → Jun 9, 2026	≥$1K
Gilbert Ray Cisneros, Jr. D · HOUSE · CA-31	Buy	27 days Nov 18, 2025 → Dec 15, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	19 days Apr 23, 2025 → May 12, 2025	≥$1K
Robert Bresnahan R · HOUSE · PA-8	Sell	30 days Apr 8, 2025 → May 8, 2025	≥$1K
Gilbert Ray Cisneros, Jr. D · HOUSE · CA-31	Sell	7 days Mar 31, 2025 → Apr 7, 2025	≥$1K
Robert Bresnahan R · HOUSE · PA-8	Buy	30 days Feb 25, 2025 → Mar 27, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	9 days Feb 25, 2025 → Mar 6, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	15 days Feb 19, 2025 → Mar 6, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	20 days Jan 17, 2025 → Feb 6, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	20 days Nov 15, 2024 → Dec 5, 2024	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,064

13F shares

1.06B

Total invested

$16.8B

Ownership

91.7%

New positions

119

Closed positions

107

Increased positions

487

Reduced positions

328

Put/Call ratio

0.58

Holder	Reported	Shares	Value	Δ Qtr
FMR LLC	8/13/2026	96.7M	$1.5B	+482.70%
BLACKROCK, INC.	8/7/2026	86M	$1.4B	+1.97%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	76M	$1.2B	+1.78%
DAVIS SELECTED ADVISERS	8/11/2026	75.2M	$1.2B	−3.81%
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	68.2M	$1.1B	+3.57%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	54.3M	$862.0M	+0.69%
STATE STREET CORP	9/22/2026	53.1M	$842.7M	+1.60%
RUBRIC CAPITAL MANAGEMENT LP	8/14/2026	34.2M	$542.6M	+2.00%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	32.8M	$520.1M	+3.02%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	30M	$476.0M	−21.77%
INVESCO LTD.	8/14/2026	20.8M	$329.8M	−5.45%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	8/14/2026	20.2M	$320.9M	+0.00%
AMERIPRISE FINANCIAL INC	8/14/2026	18.8M	$298.8M	−5.99%
MORGAN STANLEY	8/13/2026	15.1M	$240.2M	−5.97%
BANK OF NEW YORK MELLON CORP	8/6/2026	14.3M	$226.9M	+1.13%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	13.6M	$215.4M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	13.6M	$215.4M	−0.78%
GOLDMAN SACHS GROUP INC	8/14/2026	13.6M	$215.4M	−1.11%
NORTHERN TRUST CORP	8/13/2026	10M	$159.4M	−3.95%
GLENVIEW CAPITAL MANAGEMENT, LLC	8/14/2026	9.9M	$156.9M	+8.70%
LSV ASSET MANAGEMENT	8/6/2026	8.6M	$135.9M	+8.42%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	8.4M	$132.9M	−2.04%
CALLODINE CAPITAL MANAGEMENT, LP	8/14/2026	8M	$127.1M	−1.45%
DEUTSCHE BANK AG\	8/7/2026	7.9M	$125.3M	+21.17%
JPMORGAN CHASE & CO	8/12/2026	7.3M	$119.7M	+27.75%

Insider transactions

Insider	Type	Transacted	Price	Date
Groothuis Leo Frans	A-AWARD	2.5K	—	Sep 30
Simmons David S	A-AWARD	2.1K	—	Sep 30
Enrietti Andrew	M-EXEMPT	25.1K	—	Aug 15
Enrietti Andrew	M-EXEMPT	998	—	Aug 15
Enrietti Andrew	M-EXEMPT	25.1K	—	Aug 15
Enrietti Andrew	M-EXEMPT	999	—	Aug 15
Enrietti Andrew	F-INKIND	10.9K	$16.23	Aug 15
Enrietti Andrew	F-INKIND	435	$16.23	Aug 15

Analyst consensus

Hold13 analysts

Bearish · 1 · Hold · 7 · Bullish · 5

Earnings history

	EPS	Estimate
Q3 2024	$0.75	$0.68	Beat
Q4 2024	$0.54	$0.61	Miss
Q1 2025	$0.50	$0.49	Beat
Q2 2025	$0.62	$0.56	Beat
Q3 2025	$0.67	$0.62	Beat
Q4 2025	$0.57	$0.53	Beat
Q1 2026	$0.59	$0.50	Beat
Q2 2026	$0.69	$0.60	Beat

Peers

Company overview

IPO dateMar 17, 1980

CEOScott Andrew Smith

Employees30,000

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUS

ExchangeNASDAQ Global Select

Websitewww.viatris.com

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.